Utomilumab, previously known as PF-2566, represents a significant clinical avenue in inflammatory disease . This monoclonal antibody selectively blocks the activation of CD16 – a crucial component implicated in complement-mediated immunological response . Early research demonstrates impressive efficacy in ameliorating inflammation severity, espec